<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00073411</url>
  </required_header>
  <id_info>
    <org_study_id>7978</org_study_id>
    <secondary_id>F1J-US-HMCR</secondary_id>
    <nct_id>NCT00073411</nct_id>
  </id_info>
  <brief_title>Duloxetine Compared to Escitalopram and Placebo in the Treatment of Patients With Depression</brief_title>
  <official_title>Duloxetine Versus Escitalopram and Placebo in the Treatment of Patients With Major Depression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purposes of this study are to determine:

        -  The safety of duloxetine and any side effects that might be associated with it.

        -  How duloxetine compares to escitalopram and placebo (an inactive ingredient)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      duloxetine 60mg - 120mg, escitalopram 10mg - 20mg, and placebo, 8-month,
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2003</start_date>
  <completion_date type="Actual">May 2005</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To compare the onset of antidepressant efficacy for duloxetine 60 mg once-daily compared with escitalopram 10 mg once-daily.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>To compare the efficacy of duloxetine 60 mg once-daily versus escitalopram 10 mg once-daily and placebo during acute therapy</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To compare the efficacy of duloxetine 60-120 mg once-daily versus escitalopram 10-20 mg once-daily and placebo for up to 8 months of therapy</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To compare incidence of sexual dysfunction (defined by Changes in Sexual Functioning Questionnaire (CSFQ)), during acute therapy for patients treated with duloxetine 60 mg once-daily versus escitalopram 10 mg once-daily &amp; placebo.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To compare sexual dysfunction during up to 8 months of treatment with duloxetine 60-120 mg once-daily versus escitalopram 10 to 20 mg once-daily and placebo</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To compare impact of duloxetine 60 mg once-daily versus escitalopram 10 mg once-daily &amp; placebo during acute therapy &amp; during 8 months of therapy on quality of life, functional/health outcomes, &amp; patient satisfaction with study drug</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To compare impact of duloxetine 60-120 mg once-daily versus escitalopram 10 to 20 mg once-daily and placebo for up to 8 months of therapy on quality of life, functional/health outcomes, &amp; patient satisfaction with study drug</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To compare impact of duloxetine 60-120 mg once-daily versus escitalopram 10-20 mg once-daily and placebo during acute and extended therapy on resource utilization (% patients using more,less or equal number of health care providers and services)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate safety and tolerability of duloxetine 60 mg once-daily vs. escitalopram 10 mg once-daily and placebo during acute therapy</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the safety and tolerability of duloxetine 60-120 mg once-daily vs. escitalopram 10-20 mg once-daily and placebo for up to 8 months of therapy</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To compare percentage of patients taking duloxetine 60 mg once-daily versus escitalopram 10 mg once-daily and placebo requiring a dose escalation due to less than satisfactory initial response (defined by IRB supplement or investigator request)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To compare efficacy of duloxetine versus escitalopram in the placebo non-responders who enter the rescue phase</measure>
  </secondary_outcome>
  <enrollment>675</enrollment>
  <condition>Depression</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>duloxetine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>escitalopram</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Must be at least 18 of age

          -  Must meet the criteria for major depressive disorder

          -  You must be able to visit the doctor's office about once a week for 2 to 3 months.
             After that, you will need to visit the doctor's office once a month for about 6 months

          -  You must be able to take the study drug as prescribed (6 capsules per day taken
             once-daily)

        Exclusion Criteria:

          -  You are a woman and are pregnant or breastfeeding.

          -  You have a current or previous major psychiatric disorder other than depression, such
             as bipolar disorder, schizophrenia, or other psychotic disorder.

          -  You have a history of alcohol or drug dependence within the past 6 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician.</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.lillytrials.com</url>
    <description>Lilly Clinical Trial Registry</description>
  </link>
  <verification_date>July 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 20, 2003</study_first_submitted>
  <study_first_submitted_qc>November 20, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 21, 2003</study_first_posted>
  <last_update_submitted>July 30, 2007</last_update_submitted>
  <last_update_submitted_qc>July 30, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 31, 2007</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Citalopram</mesh_term>
    <mesh_term>Duloxetine Hydrochloride</mesh_term>
    <mesh_term>Dexetimide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

